Comparison of human mesenchymal stromal cells from four neonatal tissues: Amniotic membrane, chorionic membrane, placental decidua and umbilical cord

Araújo, Anelise Bergmann; Salton, Gabrielle Dias; Furlan, Juliana Monteiro; Schneider, Natália; Angeli, Melissa Helena; Laureano, Álvaro Macedo; Silla, Lúcia Mariano da Rocha; Passos, Eduardo Pandolfi; Paz, Ana Helena da Rosa

doi:10.1016/j.jcyt.2017.03.001

Cited by 62 publications

(53 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistently, the chorionic membrane and umbilical cord are considered good options for clinical application because of their characteristics of self-renewal and differentiation and mainly for their paracrine immunomodulatory and immunosuppressive effects with lower donor-associated variability. 21,22 Further, the clinical uses of mesenchymal stem cells are not encumbered by ethical considerations or legal restrictions. 23 The MSCs used in this study were isolated from human umbilical cord.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal stromal cells ameliorate acute allergic rhinitis in rats

Wang

et al. 2017

Cell Biochemistry & Function

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) have been extensively investigated as a potential antiinflammatory treatment in many inflammatory‐related diseases; however, it remains unclear whether MSCs could be used to treat acute allergic rhinitis. A rat model of allergic rhinitis was treated with MSCs. The effect of MSCs on the inflammation of allergic rhinitis was evaluated by sneezing, nose rubbing, the pathology of the nasal mucosa, and the expression of interleukin 4, tumour necrosis factor alpha, and immunoglobulin E in the serum of rats. Also, the population of MSCs isolated from umbilical cords of humans was evaluated to determine if they could inhibit the symptoms and inflammation of acute allergic rhinitis in a rat model. We observed that this population of cells inhibited sneezing, nose rubbing, and changes in the pathology of the nasal mucosa. Intriguingly, we observed that MSCs reduced the expression of interleukin 4, tumour necrosis factor alpha, and immunoglobulin E in the serum. Furthermore, MSCs reduced the expression of histamine and the recruitment of macrophages in the nasal mucosa of allergic rhinitis rats. We reasoned that the effect of MSCs on allergic rhinitis might be through its regulation of the secretion of related cytokines from macrophages during the process of acute allergic rhinitis. This work suggested that MSCs from the umbilical cords of humans could be used as a positive clinical therapy for the human disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesenchymal stromal cells ameliorate acute allergic rhinitis in rats

Wang

et al. 2017

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Isolation methods influence MSC proliferation and differentiation potential Van Harmelen et al, 2004) Source of isolation effects MSC properties (Beeravolu et al, 2016;Beeravolu et al, 2017;De Ugarte et al, 2003;Im et al, 2005;Legzdina et al, 2016) Media composition influences proliferation and differentiation capacity of MSCs (Araujo et al, 2017;Beeravolu et al, 2016;Beeravolu et al, 2017;Jin et al, 2013) Microenvironment effects cell growth and differentiation of MSCs Y. Li et al, 2015;Shekaran et al, 2015) Donor age and environmental factors effect genetic stability of MSCs (D'Ippolito et al, 1999;Malgieri et al, 2010;Mattiucci et al, 2018;Stultz et al, 2016) Promotion of tumor growth by MSCs (Lacerda et al, 2015;Ridge, Sullivan, & Glynn, 2017) Abbreviation: MSC, mesenchymal stromal/stem cell.…”

Section: Description Referencementioning

confidence: 99%

“…This review focuses on the current perspective, opportunities, and potential challenges for the use of MSCs for cell therapy and regenerative medicine applications. (Batsali et al, 2017;Beeravolu et al, 2017;Im et al, 2005;Jin et al, 2013;Vishnubalaji et al, 2012) PB Up to P5 27 hr 50% (Jumi Kim, Shin, Jeon, Chung, & Chae, 2012) UCB Up to P18 40 hr 24% (Heo, Choi, Kim, & Kim, 2016;Jin et al, 2013;Pievani et al, 2014) CL Up to P22 54 hr 59% (Araujo et al, 2017;Beeravolu et al, 2016;Beeravolu et al, 2017) WJ Up to P20 43 hr 80% (Batsali et al, 2017;Beeravolu et al, 2016;Beeravolu et al, 2017;Trivanovic et al, 2013) CPJ > P40 16 hr 92% (Bakshi, McKee, Walker, Brown, & Chaudhry, 2018;Beeravolu et al, 2016;Beeravolu et al, 2017) PC Up to P10 51 hr 16% (Araujo et al, 2017;Beeravolu et al, 2016;Beeravolu et al, 2017;Heo et al, 2016) FT-blood Up to P20 50 hr ND (Campagnoli et al, 2001;In't Anker et al, 2004) FT-BM Up to P20 33 hr 34% (Brady et al, 2014;Campagnoli et al, 2001;K.-S. Shin et al, 2009;Q. Wang et al, 2016) FT-heart Up to P15 80 hr ND (Garikipati et al, 2018) FT-liver Up to P20 52 hr ND (Campagnoli et al, 2001;In't Anker et al, 2004) FT-pancreas Up to P30 30 hr ND (Hu et al, 2003) AF Up to P7 39 hr 15% (Moraghebi et al, 2017) Abbreviations: AF, amniotic fluid; AT, adipose tissue; BM, bone marrow; CL, cord lining; CPJ, cord placenta junction; FT, fetal tissue; MSCs, mesenchymal stromal/stem cells; ND; not determined; P, passage; PB, peripheral blood; PC, placenta; UCB, umbilical cord blood; WJ, Wharton's jelly 2 | ADULT MSCs Bone marrow (BM) MSCs were first disc...…”

mentioning

confidence: 99%

Mesenchymal stem cells: Cell therapy and regeneration potential

Brown

McKee

Bakshi

et al. 2019

J Tissue Eng Regen Med

396

268

View full text Add to dashboard Cite

Rapid advances in the isolation of multipotent progenitor cells, routinely called mesenchymal stromal/stem cells (MSCs), from various human tissues and organs have provided impetus to the field of cell therapy and regenerative medicine. The most widely studied sources of MSCs include bone marrow, adipose, muscle, peripheral blood, umbilical cord, placenta, fetal tissue, and amniotic fluid. According to the standard definition of MSCs, these clonal cells adhere to plastic, express cluster of differentiation (CD) markers such as CD73, CD90, and CD105 markers, and can differentiate into adipogenic, chondrogenic, and osteogenic lineages in vitro. However, isolated MSCs have been reported to vary in their potency and self‐renewal potential. As a result, the MSCs used for clinical applications often lead to variable or even conflicting results. The lack of uniform characterization methods both in vitro and in vivo also contributes to this confusion. Therefore, the name “MSCs” itself has been increasingly questioned lately. As the use of MSCs is expanding rapidly, there is an increasing need to understand the potential sources and specific potencies of MSCs. This review discusses and compares the characteristics of MSCs and suggests that the variations in their distinctive features are dependent on the source and method of isolation as well as epigenetic changes during maintenance and growth. We also discuss the potential opportunities and challenges of MSC research with the hope to stimulate their use for therapeutic and regenerative medicine.

show abstract

“…In addition, stem cells can be harvested simultaneously from the umbilical cord tissue itself. The umbilical cord mesenchymal stem cells (UCMSC) can be taken from the amniotic membrane, the cord lining, Wharton's jelly, and the perivascular region of the umbilical cord . The umbilical cord blood and tissue contain a heterogeneous mixture of stem and progenitor cells at different stages of differentiation .…”

Section: Umbilical Cord: From Waste Materials To Source Of Therapeuticmentioning

confidence: 99%

“…The umbilical cord mesenchymal stem cells (UCMSC) can be taken from the amniotic membrane, the cord lining, Wharton's jelly, and the perivascular region of the umbilical cord. 142 The umbilical cord blood and tissue contain a heterogeneous mixture of stem and progenitor cells at different stages of differentiation. 138 It is an attractive source of stem cells because it is considered biowaste accompanying the delivery of a baby.…”

Section: Umbilical Cord: From Waste Materials To Source Of Therapeutmentioning

confidence: 99%

Tissue engineering strategies combining molecular targets against inflammation and fibrosis, and umbilical cord blood stem cells to improve hampered muscle and skin regeneration following cleft repair

Schreurs

Suttorp

Mutsaers

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

Cleft lip with or without cleft palate is a congenital deformity that occurs in about 1 of 700 newborns, affecting the dentition, bone, skin, muscles and mucosa in the orofacial region. A cleft can give rise to problems with maxillofacial growth, dental development, speech, and eating, and can also cause hearing impairment. Surgical repair of the lip may lead to impaired regeneration of muscle and skin, fibrosis, and scar formation. This may result in hampered facial growth and dental development affecting oral function and lip and nose esthetics. Therefore, secondary surgery to correct the scar is often indicated. We will discuss the molecular and cellular pathways involved in facial and lip myogenesis, muscle anatomy in the normal and cleft lip, and complications following surgery. The aim of this review is to outline a novel molecular and cellular strategy to improve musculature and skin regeneration and to reduce scar formation following cleft repair. Orofacial clefting can be diagnosed in the fetus through prenatal ultrasound screening and allows planning for the harvesting of umbilical cord blood stem cells upon birth. Tissue engineering techniques using these cord blood stem cells and molecular targeting of inflammation and fibrosis during surgery may promote tissue regeneration. We expect that this novel strategy improves both muscle and skin regeneration, resulting in better function and esthetics after cleft repair.

show abstract

Comparison of human mesenchymal stromal cells from four neonatal tissues: Amniotic membrane, chorionic membrane, placental decidua and umbilical cord

Cited by 62 publications

References 48 publications

Mesenchymal stromal cells ameliorate acute allergic rhinitis in rats

Mesenchymal stromal cells ameliorate acute allergic rhinitis in rats

Mesenchymal stem cells: Cell therapy and regeneration potential

Tissue engineering strategies combining molecular targets against inflammation and fibrosis, and umbilical cord blood stem cells to improve hampered muscle and skin regeneration following cleft repair

Contact Info

Product

Resources

About